Merck reported solid growth in key segments like immunology, diabetes, and vaccines, along with disciplined cost management and maintained full-year guidance. Management's optimistic outlook on their innovative pipeline and strategic focus likely instills investor confidence, offsetting concerns from a 2% decline in GAAP revenues.

[1]